XTALPi Delivers First-Ever Profitable Interim Report in AI-Driven Drug Discovery Sector, H1 Revenue Soars 404% YoY

　　【Pharmaceutical Network Enterprise News】Recently, XtalPi, an listed company that gathers many "cash-burning" elements, has finally released its first profitable semi-annual report: revenue in the first half of the year increased by 404% year-on-year to 517 million yuan, with an adjusted net profit of 141 million yuan.
 

Public information shows that XtalPi is a quantum physics-based platform empowered by artificial intelligence andRobotAn innovation-driven R&D platform that mainly provides solutions and services for drug and materials science research and development.
 

Previously, the company had experienced consecutive years of losses. The prospectus shows that in 2021, 2022, and 2023, XtalPi's revenues were RMB 62.799 million, RMB 133 million, and RMB 79.967 million, respectively; during the same periods, the net losses were RMB 2.137 billion, RMB 1.439 billion, and RMB 1.906 billion, respectively; the adjusted losses were RMB 271 million, RMB 437 million, and RMB 522 million, totaling RMB 1.23 billion.
 

In June 2024, XtalPi, which has yet to achieve stable profitability, opened the door to the Hong Kong Stock Exchange, becoming the first 18C company on the Hong Kong stock market. This IPO attracted eight cornerstone investors from different fields, including Successful Lotus, IntelliMed, Mammoth Medical Solutions,海棠壹号, Professor Bradley L. Pentelute, Ginkgo Fund I,百奥赛图, and FaaS Capital Longevity Limited. These eight investors collectively subscribed for HKD 337 million, accounting for 29.89% at the upper limit of the fundraising.
 

The 2024 annual report shows that XtalPi achieved operating revenue of 266 million RMB, a year-on-year increase of 53%. This allowed the company to meet the HKEX’s revenue threshold requirement of 250 million HKD for commercialized companies ahead of schedule. XtalPi applied to the Hong Kong Stock Exchange for removal of the "P" designation and received approval, becoming the first specialized technology company to successfully list on the Main Board of HKEX under Chapter 18C of the Hong Kong listing rules since the new regulations took effect. Although losses narrowed by 12.5% year-on-year, XtalPi reported an adjusted net loss of nearly 457 million RMB in 2024. Without considering adjustments, the company's loss in 2024 was 1.515 billion RMB.
 

The profit results presented in the company's semi-annual report this year have drawn significant attention. Its revenue mainly comes from two segments: the drug discovery solutions business and the intelligent robotics solutions business. During the reporting period, the drug discovery solutions business achieved strong growth, increasing by 615.2% from RMB 60.85 million in the first half of 2024 to RMB 435.2 million. This growth was primarily driven by substantial upfront payments from major collaborations and the successful achievement of corresponding milestones across multiple pipelines. The intelligent robotics solutions business also experienced rapid growth, with revenue surging by 95.9% from RMB 41.78 million in the first half of 2024 to RMB 81.86 million, mainly fueled by the rapid expansion of automated chemical synthesis services and XtalPi’s R&D solutions.
 

Before the IPO, XtalPi had undergone eight rounds of financing, with a total financing amount exceeding 5 billion yuan. The institutions participating in the financing include well-known entities such as Tencent, Sequoia China, SoftBank Vision Fund, and Google, as well as other institutions like Guoshou Equity Investment, CITIC Securities Investment, CITIC Capital, HaiSong Capital, Shunwei Capital, Fangyuan Capital, Parkway Fund, YaYi Capital, Fengrui Capital, and Renren Company.
 

It is worth mentioning that on August 29 this year, XtalPi Holdings Limited also announced that it had entered into a placement agreement with the placement agent to place up to approximately 286 million placement shares through the placement agent. According to the announcement, in addition to using the funds for company operations, product development, and mergers and acquisitions, they will also explore the application of innovative financial instruments such as RWA (Real World Assets) and RDA (Real Data Assets), as well as develop new blockchain-related businesses.
 

It is reported that the RWA Registration Platform was officially launched in Hong Kong on August 6, initiated by the Hong Kong Web3.0 Standardization Association. It will establish a full-process service system for the digitization, assetization, and financialization of RWA asset tokenization. XtalPi's AI + robotics molecular discovery platform is naturally compatible with RWA and RDA. The company plans to use the proceeds from this placement for continuous product and R&D iteration, commercial expansion, and potential acquisitions. At the same time, the company will also explore the use of innovative financial tools such as RWA (Real World Assets) and RDA (Real Data Assets). Through RWA, XtalPi Holdings Limited can digitally transform real-world assets such as R&D achievements and patents, enhance asset liquidity, broaden financing channels, inject more funding and vitality into innovative drug R&D, and gain a competitive edge in the industry.
 

Favored by capital, XtalPi's market value has been continuously rising. As of the end of August 2025, XtalPi's market value has exceeded 41 billion Hong Kong dollars.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.